Cannabis Science Inc (CBIS)

Cannabis Science Inc was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company is at the forefront of medical marijuana research and development. It works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company currently has three drugs under development, namely CS-TATI-1 targeting both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies, CS-S/BCC-1 targeting basal and squamous cell carcinomas, and a proprietary cannabis-based therapy for neurological conditions that was patented in 2013. The Company established wholly owned subsidiaries in The Netherlands to expand operations in Europe, including to enhance opportunities for studies and governmental approvals on an international basis. It is laying a foundation for entrance into the FDA and other government regulatory agencies for developing medicines for cancer, autism, Influenza, PTSD and other ailments. On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled 'Composition for the Treatment of Neurobehavioral Disorders'.